Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться

Boehringer Ingelheim

Специалисты компании

Личные визитки людей, которые сами указали это место работы и разрешили показ здесь. Имена из реестров мы не берём.

Пока никто не показал здесь свою визитку.

Работаете здесь? Покажите свою визитку: фото, должность, кнопка «Написать». Почту и телефон не показываем. Только с вашего разрешения, убрать можно в любой момент. Я здесь работаю — показать мою визитку

Нашли ошибку или чужую визитку? Сообщить модератору

4
исследования идут сейчас
84
исследования в базе
79
Россия
5
Казахстан · идут 4

Разрешения по годам

Новые препаратыБиоэквивалентность

Фазы

Фаза I 2
Фаза II 12
Фаза II–III 1
Фаза III 48
Фаза IV 9
Завершено Фаза II Россия
BEA 2180 BR; Tiotropium Bromide; Placebo · Boehringer Ingelheim

A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

2 080 участников во всех странах ClinicalTrials.gov 1205.14
Завершено Фаза III Россия
BI 1356; Placebo · Boehringer Ingelheim

A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.

245 участников во всех странах ClinicalTrials.gov 1218.35
Завершено Фаза III Россия
placebo; BIBF 1120 · Boehringer Ingelheim

A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

551 участник во всех странах ClinicalTrials.gov 1199.34
Завершено Фаза I Здоровые добровольцы Россия
Meloxicam Capsule (Test); Meloxicam Tablet (Reference) · Boehringer Ingelheim

An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Volunteers to Evaluate the Relative Bioavailability of a New Oral Formulation of Meloxicam, Movalis® Capsules 15 mg, Versus Movalis® Tablets 15 mg, After Administration Under Fasting State.

Москва 1 центр 26 участников во всех странах ClinicalTrials.gov 0107-0277
Завершено Фаза III Россия
fixed-dose combination of telmisartan 40mg+amlodipine 10mg; fixed-dose combination of telmisartan 80mg+amlodipine10mg · Boehringer Ingelheim

An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension

838 участников во всех странах ClinicalTrials.gov 1235.8
Завершено Россия
248.613 · Boehringer Ingelheim

CEE PMSS (Central Eastern European Post-Marketing Surveillance Study) First Presentation of Mirapexin in Parkinson Patients

2 448 участников во всех странах ClinicalTrials.gov 248.613
Завершено Фаза III Россия
Dabigatran; Warfarin · Boehringer Ingelheim

A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.

2 867 участников во всех странах ClinicalTrials.gov 1160.47
Завершено Фаза III Россия
Warfarin; Dabigatran etexilate · Boehringer Ingelheim

A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication

2 589 участников во всех странах ClinicalTrials.gov 1160.46
Завершено Фаза III Россия
Investigator´s choice of chemotherapy; BIBW 2992 · Boehringer Ingelheim

Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)

1 154 участника во всех странах ClinicalTrials.gov 1200.42
Завершено Россия
Empagliflozin; Sodium Glucose Transporter 2 inhibitor; Dipeptidyl-peptidase 4 inhibitor; Glucagon-like peptide 1 agonist · Boehringer Ingelheim

CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries

Москва, Санкт-Петербург и ещё 28 городов 54 центра 4 083 участника во всех странах ClinicalTrials.gov 1245-0187
Завершено Фаза III Россия
enoxaparin; tenecteplase; clopidogrel · Boehringer Ingelheim

STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms

1 899 участников во всех странах ClinicalTrials.gov 1123.28
Завершено Россия
1160.249 · Boehringer Ingelheim

Non-interventional Study Describing Patients´ Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamine K Antagonist for Stroke Prevention in Non-Valvular Atrial Fibrillation

9 472 участника во всех странах ClinicalTrials.gov 1160.249
Завершено Фаза II–III Россия
tamsulosin hydrochloride; Placebo · Boehringer Ingelheim

A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months

231 участник во всех странах ClinicalTrials.gov 527.51
Завершено Фаза III Россия
linagliptin; linagliptin · Boehringer Ingelheim

A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (One Dose, e.g. 5 mg), Administered Orally Once Daily Over 24 Weeks, With an Open Label Extension to 80 Weeks (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

701 участник во всех странах ClinicalTrials.gov 1218.17
Завершено Фаза II Россия
placebo; dabigatran etexilate; dabigatran etexilate; dabigatran etexilate; dabigatran etexilate · Boehringer Ingelheim

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

1 878 участников во всех странах ClinicalTrials.gov 1160.67
Завершено Фаза II Россия
Tiotropium bromide; Placebo; Salmeterol xinafoate · Boehringer Ingelheim

A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype

388 участников во всех странах ClinicalTrials.gov 205.342
Завершено Россия
1160.188 · Boehringer Ingelheim

Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

Москва, Санкт-Петербург и ещё 9 городов 18 центров 7 797 участников во всех странах ClinicalTrials.gov 1160.188
Завершено Фаза III Россия
fixed dose combination of telmisartan+amlodipine; amlodipine · Boehringer Ingelheim

An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy

947 участников во всех странах ClinicalTrials.gov 1235.6
Завершено Фаза II Россия
BI 10773; placebo; sitagliptin · Boehringer Ingelheim

A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy

495 участников во всех странах ClinicalTrials.gov 1245.10

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.